Open an account

Prestige Consumer Healthcare

PBH · NYSE

$49.36−$0.35 (−0.70%)TodayMarket closed ·
Prev close $49.71

About PBH

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Employees
600
Headquarters
Tarrytown, New York
Listed
Feb 10, 2005
Sector
Health Care
Industry
Pharmaceuticals
Website
prestigebrands.com

PBH key statistics

Market cap
2.34B
Price-earnings ratio
13.92
Dividend yield
—
Average volume
564.76K
Volume
536.73K
Open price
$50.35
High today
$50.37
Low today
$48.99
52 Week high
$71.07
52 Week low
$42.62

Prestige Consumer Healthcare (PBH) at a glance

As of Oct 20, 2026, Prestige Consumer Healthcare (PBH) shares are priced at $49.36, giving the company a market cap of 2.34B and a price-to-earnings ratio of 13.92.

Today the stock has traded between $48.99 and $50.37. The current price is 0.8% above the day's low and 2.0% below its high.

Volume so far is 536.73K shares, in line with the average of 564.76K shares a day.

Over the past year Prestige Consumer Healthcare has ranged from $42.62 to $71.07, and now sits 24% of the way up that range.

Prestige Consumer Healthcare met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.98 per share against an estimate of $0.8908.

The average analyst price target is $68.60, 39.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 3 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 5 analystsAvg $68.60
Low
$55.55
Now
$49.36
High
$78.75

PBH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 5.7% on average.

  1. Q4 FY24: reported $0.98 per share against an estimate of $1.15
  2. Q1 FY25: reported $0.90 per share against an estimate of $0.8691
  3. Q2 FY25: reported $1.09 per share against an estimate of $1.10
  4. Q3 FY25: reported $1.22 per share against an estimate of $1.17
  5. Q4 FY25: reported $1.32 per share against an estimate of $1.31
  6. Q1 FY26: reported $1.23 per share against an estimate of $1.40
  7. Q1 FY27: reported $0.98 per share against an estimate of $0.8908
  8. Q2 FY26: reported $0.98 per share against an estimate of $0.8908

PBH news

  • Press releasePRNewswire

    More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds

  • Press releasePRNewswire

    Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test

  • Press releaseGlobe Newswire

    Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results

  • Press releaseGlobe Newswire

    Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date

  • Press releaseGlobe Newswire

    Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes

  • Press releasePRNewswire

    Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, HBSS Investigating

  • Press releaseGlobe Newswire

    Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman Investigating

  • Press releasePRNewswire

    PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm

Similar companies

Companies in the same industry as Prestige Consumer Healthcare

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.